Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics

By administering empathogen/entactgen with psychedelic drugs, the negative effects of psychedelics such as anxiety are reduced, and the therapeutic efficacy is enhanced, leading to improved mood responses and treatment outcomes.

JP2025037974AInactive Publication Date: 2025-03-18ユニヴェルシテートスピタル バーゼル
0 Cites 0 Cited by

Patent Information

Application Number
JP2024208042
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-05-05
Filing Date
2024-11-29
Publication Date
2025-03-18
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The use of psychedelic drugs like LSD can lead to negative subjective effects such as anxiety, which can impede therapeutic outcomes and require additional interventions.

Method used

Administering empathogen/entactgen, such as MDMA, prior to or in combination with psychedelic drugs to induce positive mental states, reduce anxiety, and enhance the positive effects of psychedelic drugs.

Benefits of technology

The combination of empathogen/entactgen and psychedelic drugs improves the positive acute and long-term therapeutic efficacy by reducing negative effects like anxiety and promoting more favorable mood responses.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide a method of enhancing positive effects of a psychedelic.SOLUTION: Provided is a method of enhancing the positive effects of a psychedelic by inducing a positive psychological state in an individual using an empathogen / entactogen, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. Provided is a composition comprising an entactogen / empathogen and a serotonergic psychedelic in the same dosage form, or administered as separate compositions within a combination treatment schedule. Provided is a method of enhancing the positive effects of a psychedelic by inducing the release of endogenous monoamines, and subsequently stimulating 5-HT2A receptors.SELECTED DRAWING: Figure 1A
Need to check novelty before this filing date? Find Prior Art